4.5 Article

Cardiogenic shock: incidence, survival and mechanical circulatory support usage 2007-2017-insights from a national registry

Journal

CLINICAL RESEARCH IN CARDIOLOGY
Volume 110, Issue 9, Pages 1421-1430

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00392-020-01781-z

Keywords

Cardiogenic shock; ECMO; pVAD; Mechanical circulatory support

Funding

  1. Projekt DEAL

Ask authors/readers for more resources

A study in a German university hospital found that the incidence and use of MCS in treating cardiogenic shock patients have increased over the past decade, while hospital survival rates remain low. There are significant differences in in-hospital survival rates among different types of MCS devices.
BackgroundA central element in the management of cardiogenic shock (CS) comprises mechanical circulatory support (MCS) systems to maintain cardiac output (CO). This study aims to quantify incidence, outcome and influence of MCS in CS over the last decade.MethodsAll patients hospitalized with CS in a tertiary university hospital in Germany between 2007 and 2017 were identified utilizing the international coding system ICD-10 with code R57.0. Application of MCS was identified via German procedure classification codes (OPS).Results383,983 cases of cardiogenic shock were reported from 2007 to 2017. Patients had a mean age of 71 years and 38.5% were female. The incidence of CS rose by 65.6% from 26,828 cases in 2007 (33.1 per 100,000 person-years, hospital survival 39.2%) to 44,425 cases in 2017 (53.7 per 100,000 person-years, survival 41.2%). In 2007, 16.0% of patients with CS received MCS (4.6 per 100,000 person-years, survival 46.6%), dropping to 13.9% in 2017 (6.6 per 100,000 person-years, survival 38.6%). Type of MCS changed over the years, with decreasing use of the intra-aortic balloon pump (IABP), an increase in extracorporeal membrane oxygenation (VA-ECMO) and percutaneous ventricular assist device (pVAD) usage. Significant differences regarding in-hospital survival were observed between the devices (survival: overall: 40.2%; medical treatment=39.5%; IABP=49.5%; pVAD=36.2%; VA-ECMO=30.5%; p<0.001).ConclusionsThe incidence of CS is increasing, but hospital survival remains low. MCS was used in a minority of patients, and the percentage of MCS usage in CS has decreased. The use rates of the competing devices change over time.Graphical Abstract

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available